Short-term clinical outcomes of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with myocardial infarction: A randomized clinical trial study

Background: Reperfusion can be done through primary percutaneous coronary intervention (PPCI) and thrombolytic administration. Patients with myocardial infarction should receive antiplatelet drugs from the P2Y12 receptor inhibitor category (such as ticagrelor, prasugrel, and clopidogrel). Based on recent researches, effectiveness of ticagrelor versus clopidogrel is still debatable. Methods: A total of 128 patients who underwent PPCI, divided into two groups (Zyllt® group (600 mg received as a loading dose, maintenance with dose of 75 mg daily)) and Ticora® group (180 mg as a loading dose, maintenance with dose of 90 mg twice). Both the groups received aspirin 80 mg daily, too. They were followed up after 3 months. Results: In this study, 86.9% were men, and there was no significant difference in terms of gender and age in 2 groups. Risk factors, type of myocardial infraction (MI), number of involved and infarct-related arteries, and presence of complications and their type were not statistically different in groups (P > 0.05). Among all complications, only one person had dyspnea in the Ticora group, one patient in the Ticora group, and 3 patients in the Zyllt group had chest pain. The difference in “TIMI Score” during Time was significant (P = 0.037). Conclusion: Our study shows no difference between ticagrelor and clopidogrel after PPCI in patients with MI in terms of risk factors, type of MI, number of involved and infarct-related arteries, and presence of complications and their type, in two studied groups.